Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 11, 2005. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific share transactions and does not contain financial performance data.
Material Changes
The primary material change reported is a transfer of 25,893 Ordinary Shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991. This transaction occurred on January 10, 2005, and the company was advised of it on January 11, 2005.
Management Commentary and Risks
The filing notes that the GSK Trust is a discretionary trust where all current and former employees are potential beneficiaries. Consequently, three directors—Dr J-P Garnier, Dr T Yamada, and Mr J D Coombe—are interested in the shares held in the trust in the same manner as other employees. No specific risks, contingencies, or unusual items regarding operations were disclosed in this text.
Investor Verification Points
- Verify the impact of the 25,893 share transfer on the total outstanding share count.
- Confirm the specific holdings of directors Dr J-P Garnier, Dr T Yamada, and Mr J D Coombe through the GSK Trust.
- Review the terms of the SmithKline Beecham Employee Share Option Plan 1991 to understand vesting conditions.